Obstructive sleep apnea syndrome in patients with chronic idiopathic urticaria

Alataş, Emine Tuğba; Ünal, Yasemin; Pektaş, Suzan Demir; Kutlu, Gülnihal

doi:10.1111/dth.14060

Cited by 6 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 23 However, recent studies suggest that CU patients are at an increased risk for developing sleep-related breathing disorders compared to the general population, including OSA. 12 , 13 , 14 For example, a previous article found that 41.9% of CU patients had OSA confirmed by polysomnography that was mostly considered mild. In our study, we found that roughly 4 out of 10 CU patients had a high to intermediate risk for OSA based on screening with the STOP-Bang questionnaire.…”

Section: Discussionmentioning

confidence: 99%

“…This interesting finding is consistent with a previous study that found a positive correlation between the apnea/hypopnea index and UAS7 scores (r = 0.537, P = .002). 14 …”

Section: Discussionmentioning

confidence: 99%

“… 12 , 13 For instance, a previous study found that 40% of CU patients had OSA assessed through polysomnography, a rate which appears higher than reported for the general population. 14 It is still unclear whether CU increases the risk for developing OSA, or the latter increases the risk for CU. 13 There are many unanswered questions including what the risk is for OSA among CU patients and its influence on CU disease severity and control.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

“Chronic urticaria and obstructive sleep apnea: Is there a significant association?”

Chérrez-Ojeda

Maurer

Félix

et al. 2021

World Allergy Organization Journal

View full text Add to dashboard Cite

Background Few studies have explored the association between obstructive sleep apnea (OSA) and chronic urticaria (CU). Our study aims to fill this gap by determining the frequency of the risk categories for OSA and how they might correlate with the specific CU patient reported outcome measures urticaria activity score (UAS7), urticaria control test (UCT) and CU quality of life questionnaire (CU-Q2oL). Methods We conducted a cross-sectional study involving a cohort of 171 Latin American CU patients. Descriptive statistics were used to determine frequency and proportions for demographic and clinical variables, while a chi-squared test for association between STOP-Bang OSA questionnaire categories and both UAS7 and UCT categories was performed to analyze how such variables interact. To further assess the strength of the correlation a Cramer's V coefficient was reported. Finally, a Kendall-Tau b correlation coefficient was performed to measure the correlation between the STOP-Bang score and other independent continuous variables. Results The average STOP-Bang score was 2.5, with 24% and 21% of patients falling into the intermediate and high-risk category for moderate-to-severe OSA, respectively. There was a strong statistically significant association (Cramer's V = 0.263; p = .000) between UAS-7 categories and STOP-Bang risk categories . A similar pattern of strong significant association (Cramer's V = .269; p = .002) was observed between UCT categories and STOP-Bang risk categories. A weak positive correlation between the STOP-Bang score and the CU-Q2oL average score (τ b = 0.188, p = .001) was identified. Overall, 72.5% patients reported limitations with respect to sleep in a varied degree according to the CU-Q2oL. Conclusions Our results suggest that a considerable proportion of patients with CU are at intermediate to high risk for OSA. Higher disease activity, poor CU control, and worse quality of life were all found to be associated with an increased risk. Additional studies are needed to determine the exact link between these conditions, and to determine whether screening and treatment for OSA might benefit patients with CU.

show abstract

Section: Discussionmentioning

confidence: 99%

“…This interesting finding is consistent with a previous study that found a positive correlation between the apnea/hypopnea index and UAS7 scores (r = 0.537, P = .002). 14 …”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

“Chronic urticaria and obstructive sleep apnea: Is there a significant association?”

Chérrez-Ojeda

Maurer

Félix

et al. 2021

World Allergy Organization Journal

View full text Add to dashboard Cite

show abstract

“…Alatas et al reported OSAS in 13 (41.9%) of 31 chronic spontaneous urticaria patients. 10 Cherrez-Ojeda et al studied 171 Latin American patients with chronic urticaria and reported moderate to severe OSAS in 4 of every 10 urticaria patients. 20 In this regard, our findings were consistent with the literature.…”

Section: Discussionmentioning

confidence: 99%

Relationships between quality of life, sleep problems, and sleep quality in patients with chronic idiopathic urticaria

Ateş¹,

Fırat²,

Buhari³

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background In this study, we aimed to evaluate the sleep quality among chronic urticaria patients using the Chronic Urticaria Quality‐of‐Life Questionnaire (CU–Q2oL), sleep quality assessment tools, and polysomnography and to investigate any relationships between the obtained results. Methods The study included 21 patients diagnosed with chronic spontaneous urticaria and 19 healthy controls. We recorded the patients' sleep quality data, including CU–Q2oL, Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), and polysomnography results. Result Patients in the chronic urticaria group were more likely to have an ESS score of ≥10 (52.4% vs. 5.3%, p = 0.004) and an apnea‐hypopnea index of ≥5 (44.4% vs. 5.3%, p = 0.017) compared to the control group. In the patient group, the CU–Q2oL total score was positively correlated with sleep latency (r = 0.713, p = 0.004) and PSQI–C1 score (r = 0.726, p = 0.005), while it was negatively correlated with urticaria duration (r = −0.579, p = 0.015), apnea‐hypopnea index (r = −0.607, p = 0.021), longest apnea duration (r = −0.583, p = 0.029), total number of respiratory events (r = −0.618, p = 0.018), and apnea count (r = −0.686, p = 0.007). Conclusion We conclude that sleep‐related problems exist among a considerably large proportion of patients with chronic spontaneous urticaria.

show abstract

“…11,12 Angioedema, which is present in up to 70% of patients with CSU, may also affect sleep. 13 Wakefulness promoted by histamine released from mast cells and comorbidities such as sleep apnea 14 may also contribute to sleep interference. It is clear that sleep loss negatively affects performance at work and daily functioning, significantly impacts social lives, and is associated with lower life expectancy.…”

Section: Introductionmentioning

confidence: 99%

Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria

Giménez‐Arnau

Maurer

Bernstein

et al. 2022

Clinical & Translational All

View full text Add to dashboard Cite

Background Chronic spontaneous urticaria (CSU) negatively impacts patients' sleep, thereby reducing health‐related quality of life (HRQoL). Half of patients with inadequately controlled CSU report sleep interference often or every night, which can lead to depression, anxiety, social, and work‐related problems. Methods This randomized, double‐blind, placebo‐controlled Phase 2b core study (NCT02477332) included adult patients ≥18 years with moderate to severe CSU inadequately controlled with H1‐antihistamines. The current analysis includes patients randomized to receive ligelizumab 72 or 240 mg, omalizumab 300 mg or placebo every 4 weeks (q4w) for five injections over 20 weeks with treatment‐free follow‐up for 24 weeks. Patients could enter the open‐label extension study (NCT02649218) from Week 32 onwards if their weekly urticaria activity score was ≥12, which included an open‐label treatment (52 weeks of ligelizumab 240 mg q4w) and a 48‐week post‐treatment follow‐up. Weekly Sleep Interference Scores (SIS7, range 0 [no interference]–21 [substantial interference]), Weekly Activity Interference Score (AIS7), Dermatology Life Quality Index (DLQI) scores, and Overall Work Impairment were assessed. Results Mean baseline SIS7 scores were balanced between the treatment arms for ligelizumab 72 mg (n = 84) and 240 mg (n = 85), omalizumab 300 mg (n = 85), and placebo (n = 43). By Week 12, patients experienced large improvements in sleep interference, with least square mean (standard error) changes from baseline (CFB) in SIS7 of −7.84 (0.58), −7.55 (0.61), −6.98 (0.60), and −5.85 (0.81), respectively. By Week 12, CFB in AIS7 were −8.25 (0.57), −8.25 (0.59), −7.30 (0.60), and −5.62 (0.79), DLQI scores were −9.79 (0.77), −9.93 (0.81), −8.35 (0.79), and −6.99 (1.11), and Overall Work Impairment scores were −28.96 (3.73), −30.76 (3.71), −25.74 (3.91), and −20.13 (5.10) for ligelizumab 72 and 240 mg, omalizumab 300 mg and placebo, respectively. Improvements in each patient‐reported outcome were sustained with ligelizumab 240 mg treatment during the extension study. Conclusions Ligelizumab showed effective and sustained responses in managing sleep interference in patients with CSU, and numerically higher responses than with omalizumab and placebo. Treating the symptoms of CSU with ligelizumab improved disease burden, HRQoL, and markedly improved sleep quality.

show abstract

Obstructive sleep apnea syndrome in patients with chronic idiopathic urticaria

Cited by 6 publications

References 20 publications

“Chronic urticaria and obstructive sleep apnea: Is there a significant association?”

“Chronic urticaria and obstructive sleep apnea: Is there a significant association?”

Relationships between quality of life, sleep problems, and sleep quality in patients with chronic idiopathic urticaria

Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria

Contact Info

Product

Resources

About